Biocontainment design considerations for biopharmaceutical facilities.
This article highlights biocontainment design considerations for biopharmaceutical manufacturing facilities. The major focus of this report is on industry's use and interpretation of the regulations with specific design recommendations for a Biosafety Level 2--Large-Scale physical containment level as described by the National Institutes of Health Guidelines.
Miller
S R
SR
SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
Bergmann
D
D
D000062:Accidents, Occupational / Q000517:prevention & control; D003264:Containment of Biohazards / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D004493:Education; D004867:Equipment Design; D005160:Facility Design and Construction / Q000592:standards*; D007218:Industrial Microbiology / Q000331:legislation & jurisprudence / Q000592:standards*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000592:standards*; D014865:Waste Disposal, Fluid / Q000379:methods*